Claritev Corporation Announces Participation in Truist Securities Healthcare Disruptors & Digital Health Conference

MCLEAN, Va.--(BUSINESS WIRE)-- Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced that members of its management team will participate in the Truist Securities Healthcare Disruptors & Digital Health Conference, including a panel discussion titled “The Data Before the AI: Building the Foundation for Scalable Healthcare Intelligence” with Michael Kim, Chief Digital Officer, on Wednesday, June 24, 2026, at 1:00pm ET.

About Claritev

Claritev is a healthcare technology, data, and insights company focused on delivering affordability, transparency, and quality across the U.S. healthcare system. Led by deeply experienced associates, data scientists, and innovators, Claritev provides technology-enabled solutions fueled by decades of claims expertise. The company leverages advanced analytics and AI to power a robust enterprise platform that delivers clear, actionable insights to support affordability, price transparency, and optimized network and benefits design. By supporting key stakeholders — including payers, employers, patients, providers, and third parties — Claritev is dedicated to making healthcare more accessible and affordable for all.

Claritev serves more than 750 healthcare payers, over 100,000 employers, 60 million consumers, and 1.4 million contracted providers. For more information, visit claritev.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260623051697/en/

Investor Relations Contacts
Todd Friedman
VP, Investor Relations
Claritev
[email protected]

Media Relations Contact
Jen O’Connor
VP, Brand Marketing
Claritev
[email protected]

Source: Claritev Corporation

You May Also Be Interested In

• International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces
• TEAMSTERS ORGANIZE TWO DHL SUBCONTRACTORS IN 24 HOURS
• U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer